Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIODOSE: [177Lu]Lu-PSMA-617 in Chemo-naïve mCRPC
NCT06531499Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2024
- Primary completion
- Apr 2029
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Novartis. Primary endpoints: Time activity curves and absorbed radiation dose of AAA617 in organs, Incidence and severity of Adverse Events and Serious Adverse Events and 1 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06531499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531499.